Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 6/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937972 | 1.00 | ATM (0.57) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL22469342 | 0.90 | ATM (0.48) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL937783 | 0.86 | ATM (0.58) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL24187715 | 0.86 | ATM (0.58) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL937784 | 0.86 | ATM (0.58) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL14318305 | 0.86 | CTSL (0.53) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL28675690 | 0.85 | ATM (0.54) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL28684351 | 0.85 | ATM (0.54) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL22754646 | 0.85 | ATM (0.54) | ATMCTSKCTRB1ELANECTSL | |
| SCHEMBL28931249 | 0.85 | ATM (0.54) | ATMCTSKCTRB1ELANECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462659-A | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113874079-B | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-113874079-A | Bridged tricyclic carbamoylpyridone compounds and pharmaceutical use thereof | 吉利德科学公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20210179635-A1 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-17 | — | — | US | disclosed |
| CN-107735400-B | Cyclic sulfamoyl arylamide derivatives and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3317286-B1 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-09-11 | — | — | EP | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2475657-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | ATM 4753/4885CTSK 2579/4885CTRB1 177/4885 |
| US-20210179635-A1 | CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | NR1H4, HCCS, SLC10A1 | ATM 4380/4885CTSK 3103/4885CTRB1 1318/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | ATM 4753/4885CTSK 2579/4885CTRB1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.